Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top ...

In a deal that will end intellectual property claims in five countries, including one before the International Trade ...

These are heady days for PharmaEssentia, a biotech that got its start 23 years ago in Taiwan, went public 10 years later and ...

CDMO Lonza is strengthening its market leadership with a newly created role that puts seasoned exec Samanta Cimitan, Ph.D., ...

Jazz Pharmaceuticals has added a second overall survival win to Ziihera’s cap, bolstering the bispecific’s claim as the new ...

Late August has been rough for IV solution makers as B. Braun added to its recall tally once more, building on Baxter’s three recalls of similar products in the same time frame. | Late August has been ...

In its release on the CARDIO-TTRansform data, the ESC echoed AZ and Ionis’ point that Wainua suppressed circulating serum TTR ...

Mimrylo marks the second FDA new drug approval that Takeda has secured since CEO Julie Kim officially took the reins in June ...

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...

Bristol Myers Squibb, by way of its RayzeBio unit, has taken a big step in furthering its commitment to radiopharmaceuticals, ...